- Sort by Relevance
- Display 15 Products per page
Published: August 1, 2004 | Price: $1,995.00 – $5,990.00
The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs). This report on the U.S. market for OTC GI products presents a description of upper gastrointestinal conditions and diseases, the OTC treatments available, and clinical and business trends affecting the market, consumer behavior and attitudes, and...Published: August 1, 2004 | Price: $895.00 – $1,790.00
After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a growing awareness of the negative consequences of poor pain management. Infusion pumps were first introduced in the 1960s. These devices ushered in a whole new...Published: August 1, 2004 | Price: $995.00 – $1,910.00
Blood banking has been the most dynamic testing segment to adopt molecular diagnostics approaches since their introduction. Screening for HIV, HCV and HBV in donated blood, plasma and organs has largely been done by immunoassay procedures. In conjunction with background screening, this has become a very effective approach toward guaranteeing the safety of the blood/organ supply. However, there is a lag time between infection with these viruses and the production of antibodies against them. In some cases, such as HBV,...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
New technologies and alternatives to traditional cosmetic surgery have opened up a huge new market for anti-aging products. Cosmetic facial rejuvenation is no longer the purview of plastic surgeons, but represents a booming cash business for a large number of dermatologist and other practitioners. Botox, dermal fillers, resurfacing modalities, lasers, and other alternatives are creating a dynamic and growing marketplace and finding millions of eager patients. This 400-page report examines the competing technologies, procedures, and options available to physicians, non-physician...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...Published: July 1, 2004 | Price: $895.00 – $1,790.00
Alternative routes of administration for insulin has been one of the leading drivers of drug delivery industry. Although transdermal and transmucosal systems have shown promise and true oral delivery remains a goal, pulmonary delivery has emerged as the leading area of development. Several major players in the pharmaceutical industry have given their backing to inhaled insulin projects, and product launches are imminent. However, the exact make-up of the market, patient acceptance, and regulatory progress are still not completely clear. This...Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...Published: June 1, 2004 | Price: $1,500.00 – $3,000.00
Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. That is, the complex process of creating biologics, means that traditional definitions of bioequivalence used in the generic drug industry do not (or may not)...Published: June 1, 2004 | Price: $3,500.00 – $7,000.00
In 2003, the market for monoclonal antibodies in the treatment of cancer is just short of $2.8 billion and growing at a phenomenal rate. The market is fueled by leading products such as Rituxan and Herceptin; however, other products continue to demand more attention each year. This study reviews market data for the years 2001 to the present and forecasts the market to 2008, including Kalorama’s estimates of the competitive market share in 2008 based on the current pipeline and...Published: May 1, 2004 | Price: $3,500.00 – $7,000.00
Molecular diagnostics are seen as being a major breakthrough in medical science. While the technology itself has broad applications to such areas as agricultural bioterrorism and environmental science, medical and medical research applications have provided the primary focus. As a result, great things have been predicted for the development and use of new therapeutics based on molecular testing approaches. The primary molecular diagnostics approaches are based on two major database sciences (genomics and proteomics) and their relationship to disease and...Published: April 1, 2004 | Price: $1,995.00 – $3,990.00
The recent terrorism events, in addition to the ease of travel that allows infectious diseases to spread, and technology developments drive the renewed interest in clinical and environmental infectious disease diagnostics. The combined public health and bio-terrorism markets of several bacterial and protozoan diseases are estimated to be nearly $100 million. This report, the final volume of the Diagnostics for Emerging Infectious Disease Threats series, focuses on diagnostic testing for 11 bacterial and protozoal diseases in clinical and environmental testing:...Published: April 1, 2004 | Price: $3,500.00 – $7,000.00
Changing demographics are spurring dynamic growth in the interventional radiology market. The angioplasty balloon, coronary stent, vascular closure, and other associated equipment markets will experience healthy growth over the next 5 years. Persons over the age of 65 will be a major segment of the population in coming years. Chronic diseases and unhealthy habits such as smoking, lack of exercise, and poor diet are resulting in an epidemic of obesity and concomitant cardiac conditions. These factors and others will drive...Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or blocks the ability of cells to divide and multiply. Blood and tissue growth factors have become exciting targets for compounds intended to inhibit or slow the mechanisms involved in their function or growth. This report highlights the research into, and the current and potential key world markets for, products that...Published: March 1, 2004 | Price: $795.00 – $1,590.00
The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts. This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts...Published: March 1, 2004 | Price: $3,995.00 – $7,990.00
A host of new and old infectious diseases have emerged on the world stage, presenting familiar and novel challenges to public health officials. New strains of once controlled bacteria, new immunocomprimised patient populations, and new bioterror threats have spurred diagnostics companies to develop new tests and kits to meet the demand. Kalorama has assembled the vital data developers and marketers need to understand the competitive and commercial landscape in three volumes: Prion Disease; Viral Disease ; and Baterial & Protozoal...